1. Home
  2. GPRE vs DRUG Comparison

GPRE vs DRUG Comparison

Compare GPRE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Green Plains Inc.

GPRE

Green Plains Inc.

HOLD

Current Price

$17.06

Market Cap

812.2M

Sector

Industrials

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$71.89

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRE
DRUG
Founded
2004
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
812.2M
744.9M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
GPRE
DRUG
Price
$17.06
$71.89
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$12.57
$129.25
AVG Volume (30 Days)
1.3M
244.9K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$2,091,680,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.85
N/A
P/E Ratio
$40.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.08
$31.80
52 Week High
$19.65
$123.75

Technical Indicators

Market Signals
Indicator
GPRE
DRUG
Relative Strength Index (RSI) 53.76 48.39
Support Level $14.01 $66.22
Resistance Level $17.94 $71.91
Average True Range (ATR) 0.96 4.96
MACD 0.04 0.09
Stochastic Oscillator 40.46 50.51

Price Performance

Historical Comparison
GPRE
DRUG

About GPRE Green Plains Inc.

Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: